Patents by Inventor Vivian R. Albert
Vivian R. Albert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120213777Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: April 30, 2012Publication date: August 23, 2012Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 8216569Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: October 31, 2007Date of Patent: July 10, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 8206708Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: April 28, 2011Date of Patent: June 26, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Publication number: 20110229466Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: April 28, 2011Publication date: September 22, 2011Applicant: Human Genome Sciences, Inc.Inventors: Craig A. ROSEN, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 7850963Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: April 3, 2007Date of Patent: December 14, 2010Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20100292441Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to GMAD. Such antibodies have uses, for example, in the prevention and treatment of both insulin- and non insulin-dependent diabetes mellitus (i.e. Type I and Type II diabetes) and other related disorders. The invention also relates to nucleic acid molecules encoding anti-GMAD antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially diabetes and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to GMAD.Type: ApplicationFiled: January 28, 2009Publication date: November 18, 2010Inventors: Kevin P. Baker, Vivian R. Albert, Partha Chowdhury
-
Publication number: 20090226429Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: ApplicationFiled: January 18, 2008Publication date: September 10, 2009Applicant: Human Genome Sciences, Inc.Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Patent number: 7550569Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to GMAD. Such antibodies have uses, for example, in the prevention and treatment of both insulin- and non insulin-dependent diabetes mellitus (i.e. Type I and Type II diabetes) and other related disorders. The invention also relates to nucleic acid molecules encoding anti-GMAD antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially diabetes and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to GMAD.Type: GrantFiled: September 8, 2004Date of Patent: June 23, 2009Assignee: Human Genome Science, Inc.Inventors: Kevin P. Baker, Vivian R. Albert, Partha Chowdhury
-
Publication number: 20090023224Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: April 3, 2007Publication date: January 22, 2009Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Publication number: 20080286288Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: October 31, 2007Publication date: November 20, 2008Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 7402312Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention also relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: November 19, 2004Date of Patent: July 22, 2008Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 7361341Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: GrantFiled: March 29, 2006Date of Patent: April 22, 2008Assignee: Human Genome Sciences, Inc.Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Patent number: 7348003Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: GrantFiled: November 12, 2004Date of Patent: March 25, 2008Assignee: Human Genome Sciences, Inc.Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Patent number: 7208582Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: April 12, 2002Date of Patent: April 24, 2007Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 7109302Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to GMAD. Such antibodies have uses, for example, in the prevention and treatment of both insulin- and non insulin-dependent diabetes mellitus (i.e. Type I and Type II diabetes) and other related disorders. The invention also relates to nucleic acid molecules encoding anti-GMAD antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially diabetes and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to GMAD.Type: GrantFiled: March 28, 2003Date of Patent: September 19, 2006Assignee: Human Genome Sciences, Inc.Inventors: Kevin P. Baker, Vivian R. Albert, Viktor Roschke
-
Patent number: 7064189Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: GrantFiled: May 7, 2002Date of Patent: June 20, 2006Assignee: Human Genome Sciences, Inc.Inventors: Theodora Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Patent number: 6900033Abstract: Binding polypeptides comprising specific amino acid sequences are disclosed that specifically bind ACE-2 protein or ACE-2-like polypeptides. The binding polypeptides can be used in methods of the invention for detecting, isolating, or purifying ACE-2 protein or ACE-2-like polypeptides in solutions or mixtures, or biological samples. The invention also relates to nucleic acid molecules encoding these ACE-2 binding polypeptides, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention also relates to methods and compositions for detecting, diagnosing, prognosing, preventing, treating or ameliorating a disease or disorder associated with aberrant ACE-2 or ACE-2 receptor expression or inappropriate function of ACE-2 or ACE-2 receptor, comprising use of ACE-2 binding polypeptides or fragments or variants thereof, that specifically bind to ACE-2.Type: GrantFiled: June 3, 2002Date of Patent: May 31, 2005Assignee: Human Genome Sciences, Inc.Inventors: Tom J. Parry, Les Sekut, Craig A. Rosen, Vivian R. Albert, Indrajit Sanyal, Lili Huang, Charles R. Wescott
-
Publication number: 20040121429Abstract: Binding polypeptides comprising specific amino acid sequences are disclosed that specifically bind ACE-2 protein or ACE-2-like polypeptides. The binding polypeptides can be used in methods of the invention for detecting, isolating, or purifying ACE-2 protein or ACE-2-like polypeptides in solutions or mixtures, or biological samples. The invention also relates to nucleic acid molecules encoding these ACE-2 binding polypeptides, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention also relates to methods and compositions for detecting, diagnosing, prognosing, preventing, treating or ameliorating a disease or disorder associated with aberrant ACE-2 or ACE-2 receptor expression or inappropriate function of ACE-2 or ACE-2 receptor, comprising use of ACE-2 binding polypeptides or fragments or variants thereof, that specifically bind to ACE-2.Type: ApplicationFiled: June 3, 2002Publication date: June 24, 2004Inventors: Tom J. Parry, Les Sekut, Craig A. Rosen, Vivian R. Albert, Indrajit Sanyal, Lili Huang, Charles R. Wescott
-
Publication number: 20030190685Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: ApplicationFiled: May 7, 2002Publication date: October 9, 2003Applicant: Human Genome Sciences, Inc.Inventors: Theodora Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Publication number: 20030180296Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR7. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR7 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR7.Type: ApplicationFiled: December 19, 2002Publication date: September 25, 2003Inventors: Theodora Salcedo, Craig A. Rosen, Vivian R. Albert, Robin Humphreys, Tristan Vaughan